-
Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis.
2023
Annals of Dermatology 2023;35(1):6-10
-
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
2023 Jul 7
Br J Dermatol 2023 Jul 7;189(1):132-134
-
Change in the Usage of Complementary and Alternative Medicine in the Era of Biologics Among Korean Patients With Psoriasis.
2023 Jul 3
J Korean Med Sci. 2023 Jul 3;38(26):e204. doi: 10.3346/jkms.2023.38.e204
-
Therapeutic effect of dupilumab to systemic and vascular inflammation in adults with severe atopic dermatitis.
2023 May 22
Acta Derm Venereol 2023 May 22;103:adv5320. doi: 10.2340/actadv.v103.5320
-
Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
2023 Nov-Dec
Indian J Dermatol Venereol Leprol . 2023 Nov-Dec;89(6):928
-
중등증-중증 한국인 건선 환자에서 Risankizumab 치료의 효과 및 안전성에 관한 연구
2023
대한피부과학회지 2023;61(6):360∼367
-
Basic Therapeutic Approach for Patients with Plaque Psoriasis - Korean Expert Consensus Using the Modified Delphi Method.
2023 Jun
Ann Dermatol. 2023 Jun;35(3):173-182
-
Long-term analysis of ustekinumab therapy for moderate to severe psoriasis in Korea : A five-year real-world data.
2022
대한피부과학회지 2022;60(3):151-158
-
중등증-중증의 한국인 건선 환자에서 Guselkumab의 효과와 안전성에 관한 연구
2022
대한피부과학회지 2022;60(9):559-565